Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1361909 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
A weak antagonist of the pyrimidinergic receptor P2Y14 containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first reported non-nucleotide antagonists of this receptor. Compound 18q was identified as a 10 nM P2Y14 antagonist with good oral bioavailability and provided sufficient exposure in mice to be used as a tool for future in vivo studies.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniel Guay, Christian Beaulieu, Michel Belley, Sheldon N. Crane, Jeancarlo DeLuca, Yves Gareau, Martine Hamel, Martin Henault, Huda Hyjazie, Stacia Kargman, Chi Chung Chan, Lijing Xu, Robert Gordon, Lianhai Li, Yael Mamane, Nicolas Morin,